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ABSTRACT
Teriparatide (TPTD) is one of the medications commonly prescribed for the treatment of
osteoporosis since its approval in November 2002 by the U.S. Food and Drug Administration.
While some preclinical toxicological studies have linked the drug to a dose-dependent increase
in the occurrence of osteosarcoma, clinical trials showed the benefits outweighing the risk for
TPTD-induced human osteosarcoma. The objective of this qualitative review was to qualitatively
assess the literature for the association of osteosarcoma and the usage of TPTD in animal and
human subjects. Studies were selected from all available records in the electronic databases
covering the period from January 1, 2002, to September 30, 2020. While using rats as the study
specimen showed some risks to osteosarcoma dependent on dose and duration of administration,
clinical trials proved TPTD to be a safe treatment in humans. It is worthwhile investigating longer
treatment periods than the 2 years labeled period for TPTD for safety purposes.
Keywords: Osteosarcoma, safety studies, teriparatide, toxicological studies

O

INTRODUCTION

steoporosis, literally meaning porous bone, is a major
and growing chronic skeletal disease characterized
by decreased bone density and microarchitectural
deterioration of bone tissue.[1-3] It was found that
approximately 200 million women around the world suffer
from osteoporosis.[2] Estimates show that this disease affects
almost 10.2 million US citizens aged 50 years or older.[1] At
a local scale in the United Arab Emirates, it was found that
24% and 2.5% (average age 42 years) of the population suffer
from osteopenia and osteoporosis, respectively.[4] In 2007,
it was revealed that almost half of women aged 50 or older
and around one out of five men of the same age suffer from
fractures caused by osteoporosis.[5]
Teriparatide (TPTD) is a recombinant form of parathyroid
hormone (PTH) analog that is composed of the first 34 amino
acids of the endogenous hormone.[6] PTH and PTH-related
protein (PTHrP) employ their effects through binding to
the PTH/PTHrP receptor, which is conveyed in many tissues
120	
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including on the surface of osteoblasts, osteocytes, and renal
tubule cells.[7,8] TPTD has direct effects on bone formation
through a process of stimulation of osteoblast activity and
combined with the inhibition of their apoptosis,[9] causes
a rapid increase in bone formation because of the Tashjian
effect.[10] This effective anabolic bone formation promoting
agent is used sometimes off-label to speed fracture healing.[11]
TPTD is the only anabolic agent prescribed to postmenopausal
women at high risk for bone fracture or with a family history
of osteoporotic fractures, subjects with multiple risk factors
for bone fracture, and for patients who have not responded
adequately to other osteoporosis treatments.[12] The medicine is
marketed by Eli Lilly Company with brand name called Forteo®
and received approval from the Food and Drug Administration
in November 2002 for the treatment of osteoporosis in men
and postmenopausal women who are at high risk for having a
bone fracture.[13]
The safety aspect of TPTD has been a concern[14] because
there is some theoretical basis for osteosarcoma supported
by several preclinical toxicology studies on rats showing a
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dose-dependent increase in the occurrence of osteosarcoma.
[15]
Osteosarcoma, also known as osteaogenic sarcoma, is a
primary malignant bone tumor. It is a sarcoma in which the
neoplastic cells produce osseous matrix.[16] The cancer cells
look like an early form of bone responsible for new bone
tissues in the human body. However, these bone tissue forms
in osteosarcoma cases are not as strong as the normal bones.
Most osteosarcoma cases occur mainly in adolescents
and the elderly ages and slightly higher incidence in males
than females. Affected areas in individuals are where
bones are growing quickly, such as the ends of leg and arm
bones. A letter to the editor published in 2006 showed that
the occurrence of osteosarcomas in women 60 years old or
older is almost one in 250,000/year.[17] Because of this low
incidence of osteosarcoma, Tashjian and Chabner called for
careful post-marketing surveillance for the use of TPTD and
any accompanied bone tumor.[18]
Since there has been a long time (more than 17 years)
since the approval and marketing of TPTD, it is likely that the
risk for osteosarcoma would be established. Therefore, this
qualitative review of the possible association of osteosarcoma
with the use of TPTD in humans and animals would be
warranted for the future therapy options and additional
research.

LITERATURE REVIEW
This is a systematic review that qualitatively describes the
relationship between TPTD and osteosarcoma using relevant
publications available in indexing databases. This process, as
shown in Figure 1, was based on pre-determined inclusion and
exclusion criteria following PRISMA guidelines. PubMed and
Google Scholar databases were used in the study to conduct
and filter search outcomes. These databases are used by many
researchers as they provide access to peer-reviewed literature
and information in animal and human subjects.[19,20]

SELECTION CRITERIA
The screened publications from the search results were
selected based on five inclusion and four exclusion criteria.
The inclusion criteria used in this study restrict the selected
publications to be a clinical trial, case–control, cohort, case
report, case series, and pre-clinical animal studies. Exclusion
limits included studies published before 2002, the safety
assessment that does not include osteosarcoma associated with
the use of TPTD, studies assessing osteosarcoma using other
osteoporosis medications, and the studies that cover Paget’s
disease, a history of irradiation, or hyperparathyroidism.

PRE-CLINICAL STUDIES
All the studies done on rodents linked TPTD intake and
osteosarcoma cases. These studies thoroughly investigated the
effect of TPTD treatment on different rodent genders, different
dose levels, and different treatment durations on the incidents
of osteosarcoma. Jolette et al. conducted a study to define a
non-carcinogenic dose of recombinant human PTH 1–84, on
Fischer-344 rats for 2 years injected subcutaneously daily (0,
10, 50, and 150 μg/kg/day).[21] The study used 720 male and
female rats (9–11 weeks old) segregated into six groups and
121	
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found at the end of the study that high doses of PTH were
associated with a significant increase of osteosarcoma. Their
study was supported later by other authors[15] who studied
Sprague-Dawley rats (SD rats) to assess osteosarcoma after
long-term therapy with TPTD. At the end of this study, results
showed osteosarcoma incidents in all treated groups and
suggested that osteosarcoma in SD rats depends on both dose
level and treatment duration. The rats’ model was studied also
by other authors and was found to develop osteosarcoma in
association with bone formation when using TPTD.[22,23]
Chen et al. used different animal species involving 60
adult cynomolgus ovariectomized monkeys treated with
TPTD, aging around 9 years old.[24] Treatment was scheduled
for 18 months and at the end of the experiment histological
samples and radiographs were interestingly confirming that
no proliferative bone lesions were detected. In the same year,
Fox et al. published a study designed to assess the safety and
pharmacodynamic effects on bone, by studying 28 mature
ovariectomized rhesus female monkeys with PTH (1–84).[25] At
the end of the experiment, results compared with the control
animals showed an increase in BMC in treated monkeys and no
bone tumors were found at necropsy confirming the previous
results. The next year Vahle et al. published research in which
they also used the monkeys and confirmed the previous
findings.[26]
One study used 44 male white rabbits to study the effect
of TPTD on subjects’ bone mass volume compared to control
groups.[27] Histological studies were performed at the end
of this study, and the results did not show any evidence of
osteosarcoma in the tested animals. However, the study was
not designed to assess the safety of TPTD, so the results cannot
be generalized, but has been presented here for reference.
Table 1 summarizes pre-clinical studies of the use of TPTD and
the development of osteosarcoma if any.
Among the three animal species reviewed (i.e., rats,
rabbits, and monkeys), only the rat animal model developed
osteosarcoma. However, the fact that the drug was administered
to rat species at doses and duration many folds relative to
the human administration may not allow the carcinogenic
effect to be extrapolated to human subjects. For example, in
the Jolette et al. work, the duration of daily subcutaneous
dose is equivalent to almost the whole average lifespan
Fischer-344 rats. In addition, the low dose of 10 μg/kg/day
was comparable to the control, but this dose is 4.6-fold higher
than the maximum human dose of 100 μg/day.[28] On the other
hand, the similarity of skeletal biology between monkeys and
humans suggested that TPTD would be safe in humans, even
though there is non-similarity in the life span (20 years for
monkeys compared to 76 for humans) and keeping in mind
the 18 months of treatment for monkeys imply about 8-fold
that recommended for humans. The monkeys’ and rabbits’
studies provided some assurance regarding the safety of the
treatment in human subjects. However, they also indicated
that the efficacy of the treatment can be gradually lost after
the treatment period.

CLINICAL STUDIES
Clinical studies gave a better view of the relationship between
TPTD and the possibility of developing osteosarcoma. Many
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Figure 1: Flowchart of literature review methodology for the collection of publications for teriparatide and osteosarcoma in human and animal
subjects for the year 2002–2020

clinical studies have been conducted to monitor patients
undergoing TPTD therapy, some of these studies focused on
female individuals, others on males and some were on mixed
genders. All came to the same conclusion proving the safety of
TPTD treatment regarding the risk of developing osteosarcoma
when taken within the limits already defined for the therapy.
These limitations of TPTD therapy requested that patients did
not undergo radiation therapy before treatment, did not suffer
from Paget’s disease of bone, and are not children or young
adults with open epiphyses and that the therapy period does
not extend beyond 2 years.[29]
Prince et al. studied a total of 1637 postmenopausal
women with osteoporosis.[30] They were randomly divided
122	
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into three groups; placebo, TPTD 20 μg/day, and TPTD 40 μg/
day. They demonstrated the positive effects of TPTD therapy
in reducing non-vertebral fractures in the combined treatment
groups, which were sustained during the 50 months involving
both treatment and follow-up. In the safety aspect of this study,
none of the women had any bone malignancy or osteosarcoma
resulting from the treatment.
Later on, another study designed as an open-label,
multicenter trial was conducted on 198 postmenopausal
women treated with TPTD (20 μg/day) in the United States.
Female patients from 11 different centers who were at least
50 years old, had a previous clinical diagnosis of osteoporosis,
and had been previously treated for 18 months minimum with
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Table 1: Summary of the pre-clinical research studies reporting on osteosarcoma incidents with the use of teriparatide
Reference

Watanabe
et al.[15]

Vahle
et al.[22]

Vahle
et al.[23]

Vahle
et al.[26]

Jolette et al.[28]

O’Loughlin
et al.[27]

Chen
et al.[24]

Year of
publication

2012

2004

2002

2008

2006

2009

2007

Journal

The Journal of
Toxicological
Sciences

Toxicologic
Pathology

Toxicologic
Pathology

JBMR

Toxicologic
Pathology

SPINE

JBMR

Subjects

A total of 1265
rats divided
into five studies
to assess
carcinogenicity,
reproducibility
of study, the
relation between
age of rat at the
initiation of the
treatment and
induction of the
osteosarcoma,
the relation
between
duration of the
treatment term
and the risk of
osteosarcoma,
and toxicokinetic
study

A total of
480 rats
divided into
eight groups
(60/group),
to assess the
effect of level
dose and
duration of
action in the
induction
of the
osteosarcoma

A total of 480
Fischer rats
divided into
four groups
(60/sex/group) to
assess the skeletal
changes in rats
when given daily
doses of rPTH
(1–34) for 2 years

A total of 60
monkeys,
9-year-old
cynomolgus
macaques,
ovariectomized
and divided
into two
groups, vehicle
control and
treatment
groups

A total of 720
male and female
Fischer rats (9–11
weeks old), divided
into six groups to
assess the effect of
the dose level at
the induction of
osteosarcoma

A total of
44 male
white rabbits
divided into
two groups

A total of 60
monkeys,
cynomolgus (Macaca
fascicularis) of
9 years of age,
given TPTD
1.0 μg/kg/day, TPTD
5.0 μg/kg/day for
18 months

Main
Outcome

31 total cases of 20 cases are
osteosarcoma in the total
the five studies number of
osteosarcoma
cases among
the eight
groups

66 in male
and 42 in
female cases of
osteosarcoma

No bone
proliferation
lesions or
microscopic
osteosarcoma
seen

Total numbers of
osteosarcoma were
54, 40 in male and
female, respectively.
Total numbers
of metastatic
osteosarcoma
were 26 and 16 in
male and female,
respectively

Histological
studies did
not show any
evidence of
osteosarcoma

No bone
proliferation lesions
or microscopic
osteosarcoma were
seen

either antiresorptive treatments: Alendronate 70 mg/week
or raloxifene 60 mg/day were recruited.[31] The study results
indicated that none of the patients developed osteosarcoma.
Using eligible male patients (n = 437) from 37 centers
in 11 countries aging between 30 and 85 years, they were
randomly assigned to three groups; placebo group, TPTD
20 μg/day, and TPTD 40 μg/day.[32] The results showed three
cancer incidents occurring in the placebo group as well in
the 20 µg TPTD group, while none in the 40 µg TPTD group.
However, none of these cases was of osteosarcoma. In 2013,
Koski et al. studied the effectiveness of TPTD in clinical
practice, which comprised 119 osteoporotic patients receiving
20 μg/day TPTD for about 539 days as a median duration.[33]
The follow-up period varied from a few months to 2 years. It
was found that BMD has increased by a mean of 0.9% in the
total hip, 2.1% in the femoral neck, and 8.5% in the lumbar
spine. Adverse events were limited to leg pain, nausea, and
dizziness with no cases of osteosarcoma reported in support
of previous studies.
In a large case–control study, concerning the Danish
population and the impact of recombinant PTH (rPTH) on
malignancy and mortality compared to 4104 patients receiving
rPTH with 40,953 patients not receiving the treatment.[34] The
period covered was 1995 through 2010 and the participants
in the case group comprised 80.3% of female patients. No
excessive risk of cancer was reported other than lung cancer
in the group receiving rPTH. The authors described that their
123	
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study does not support the claim of the possible link between
rPTH treatment and the development of osteosarcoma with no
cases reported in the Danish population since the introduction
of rPTH to the Danish market. On the other hand, nine
osteosarcoma patients were found among controls. It is worth
mentioning that the authors of the study used broad ICD-10
codes C40-C41 which can obscure a real relationship between
primary osteosarcoma and rPTH. This means that the study
could have captured many types of bone-related tumors. This
gives additional assurance to the safety of rPTH. On the other
hand, evidence from retrospective studies is generally regarded
as weaker compared to controlled clinical trials involving large
groups.
In a recent publication evaluating the safety and
effectiveness of daily TPTD in Japanese patients with
osteoporosis and at high risk of fracture, a 24-month postmarketing surveillance study was conducted.[35] Individuals
(n = 1847) from 238 sites across Japan were selected, of which
92% were female and 90.8% of them were postmenopausal.
Through the safety profile of this study, the author reported
that there were no cases of osteosarcoma.
An interim 7 years surveillance study 2003–2009 was
published as part of ongoing US 15 years post-marketing
surveillance for adult osteosarcoma associated with TPTD. The
study reported one case of osteosarcoma in the TPTD-treated
group, which was the single reported case from 430,000.[36]
However, the incident reported that the patient previously
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No case of
osteosarcoma was
reported
No patients in the rPTH
No reports of
group were registered with osteosarcoma
osteosarcoma compared
with nine patients among
the controls
No occurrence of
osteosarcoma
No cases of
osteosarcoma
No cases of
osteosarcoma were
observed in the
teriparatide cohort
Main
Outcome

No osteosarcoma
patient who had
a prior history of
TPTD treatment

There were no
deaths or reports of
osteosarcoma

119 individuals
(113 women and
six men), who
received TPTD at a
dosage of
20 μg/day
198 postmenopausal
women with
osteoporosis, who
had previously
treated with
alendronate or
raloxifene for
18 months
4104 patients diagnosed
with osteoporosis
receiving TPTD (case
group) compared with
40,953 patients not
receiving the treatment
(controls)
1637
postmenopausal
women with
osteoporosis
437 elderly
osteoporotic
men, age 30–85
years
153–316 elderly
men and women
with an average
age of 76.9
Subjects

1448
osteosarcoma
cases identified
by 15 registers
2003–2009

1847 Participants
were patients with
osteoporosis, older
age injected 20 μg
TPTD daily for 24
months

Annals of
Medicine
Osteoporosis
International
Osteoporosis International
JBMR
JBMR
Pharmacoepidemiol
Drug Saf.
Journal

JBMR

Clinical Intervention
in Aging

2013
2008
2014
2012
2003
Year of
Publication

2020

2005

2016

Clinical
Cohort study
Clinical
Case–control study
Cohort
Cohort
Study
design

Case–control
study

Case–control
study

Wermers
et al.[31]
Nishikawa
et al.[35]
Bang et al.[34]
Prince
et al.[30]
Andrews
et al.[36]
Orwoll
et al.[32]
Gilsenan
et al.[45]
Citation

Table 2: Summary of the clinical and observational research studies reporting on osteosarcoma incidents with the use of teriparatide

Koski et al.[33]
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went through radiation therapy for prostate cancer, a
contraindication to the administration of TPTD . More recently,
an entire 15 years of surveillance results were published,
which indicated that the incidence of osteosarcoma associated
with TPTD was not different from what would be expected
based on the background incidence rate of osteosarcoma.
[37]
In one case report of a 22-year-old Persian man, the
patient developed osteoblast hyperactivation state observed
during treatment with TPTD for 7 months.[38] However, the
authors did not preclude the patient’s history as possible
cause. Another case report suggested the acceleration of the
growth of pre-existing bone tumor of the femur following
2 months TPTD treatment.[39] While TPTD is contraindicated
in irradiated bones, two patients with tongue cancer and late
emerging osteoradionecrosis were successfully treated with
TPTD for 4–6 months.[40] This was indicated by the progress
of osteoradionecrosis, and bone defect regenerating well.
Therefore, such published cases cannot prove or refute the
usefulness of TPTD in pre-existing bone tumor. For a summary
of the clinical studies reporting on osteosarcoma incidents
associated with the use of teriparatide, refer to Table 2.
Research indicated that when TPTD is discontinued, BMD
starts to decrease necessitating the prompt administration of
antiresorptive therapy.[41-43] Since TPTD therapy is supported by
long post-marketing safety profile, it is worthwhile investigating
longer treatment period and perhaps indefinitely considering the
old age of the affected individuals as the case in the management
of diabetes by SC insulin injections.[19,20] The 2-year limit set for
TPTD therapy is based on the expert review that the osteosarcoma
found in rats is unlikely to occur in humans with the treatment
of up to 2 years.[30] Furthermore, controlled clinical trials did
not cover the treatment period exceeding 2 years to uncloud the
longer time safety of TPTD. A follow-up study in clinical practice
settings showed after the discontinuation of TPTD, anti-fracture
efficacy may persist for up to 18 months.[44]

CONCLUSION
Pre-clinical investigations are important in finding demonstrating
drug safety and toxicity and are, therefore, essential before
clinical trials begin. Unfortunately, these non-clinical studies
are usually done using much larger doses and for a much
longer duration (3–60 times) than would be required in human
subjects. In several cases, the applicability of findings to humans
is also questioned by the differences between animal species. For
example, while studies done using rats revealed that TPTD can
cause osteosarcoma, results from rabbits and monkey indicated
a safe and effective therapy. The biology and structure of bone
in human differs from the studied rats, as rodents lack osteonal
remodeling and exhibit skeletal growth throughout life.
Clinical trials and post-marketing surveillance have
undoubtedly proved the efficacy and safety of the TPTD. The
efficacy of TPTD does not persist after its discontinuation and it
was advocated to start an antiresorptive therapy immediately
thereafter. Considering the therapy contraindications
discussed earlier, that is, avoiding TPTD therapy with prior
radiation therapy, having no history of Paget’s disease of bone,
and avoiding TPTD therapy for children or young adults with
open epiphyses, it is worthwhile investigating the usefulness
and safety of therapy over a period lasting more than 2 years.
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